SCHEMBL10036030

SCHEMBL10036030

CCN1C(=O)/C(=C\C=C2/Sc3ccccc3N2CC)N(CC)C1=S

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 14/20 0.74
KMT2A Q03164 14/20 0.74
MAPT P10636 12/20 0.74
ALDH1A1 P00352 10/20 0.74
MAPK1 P28482 5/20 0.74
NPC1 O15118 4/20 0.74
RAB9A P51151 4/20 0.74
THRB P10828 2/20 0.74
SMN1; SMN2 Q16637 5/20 0.67
LMNA P02545 1/20 0.61
OPRK1 P41145 1/20 0.56
USP2 O75604 3/20 0.54
CRHBP P24387 2/20 0.54
CRHR2 Q13324 2/20 0.54
IDE P14735 1/20 0.54
HPGD P15428 2/20 0.51
HTT P42858 2/20 0.51
TDP1 Q9NUW8 2/20 0.49
RECQL P46063 1/20 0.49
NPSR1 Q6W5P4 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4623964 1.00 MEN1 (0.74) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL13026070 0.90 KMT2A (0.87) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL10036033 0.90 MEN1 (0.87) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL13709032 0.89 MEN1 (0.69) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL12388178 0.87 MEN1 (0.84) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL30767820 0.80 MEN1 (0.87) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL7022919 0.80 MEN1 (0.87) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL10036064 0.80 MEN1 (0.87) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL7022922 0.80 MEN1 (0.87) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL9191749 0.80 MEN1 (0.75) MEN1KMT2AMAPTALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120035187-A1 ANTI-NEURODEGENERATIVE DISEASE AGENT KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) 2012-02-09 US disclosed
US-20120035187-A1 ANTI-NEURODEGENERATIVE DISEASE AGENT KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) 2012-02-09 US disclosed
US-20100276670-A1 PHOTOELECTRIC DEVICE, IMAGING DEVICE, AND PHOTOSENSOR FUJIFILM CORPORATION (JP) 2010-11-04 US disclosed
US-20100276670-A1 PHOTOELECTRIC DEVICE, IMAGING DEVICE, AND PHOTOSENSOR FUJIFILM CORPORATION (JP) 2010-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035187-A1 ANTI-NEURODEGENERATIVE DISEASE AGENT SNCA, PSEN1, CDR2 MEN1 2218/4885KMT2A 2624/4885MAPT 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.